Alumnus
By Shashanka Muppaneni, Srikant Vaidyanathan, Jason Jager, David Tompkins, Maximilian Roth, and Maeve Nagle
One segment of advanced diagnostics firms—the next-generation sequencing (NGS) clinical testing labs that run genetic tests—are at an inflection point, based on rapid advances in sequencing technology. In the past, companies could differentiate themselves primarily by reducing costs. Today, genetic sequencing is too fast and cheap for that, shifting the competitive dynamics in the industry. In this new environment, companies also need to expand their offerings to reflect growing preferences for targeted, multi-omic content and whole genome sequencing, among other services.
These are significant shifts, and it’s not yet clear how they will reshape the market for NGS clinical testing labs and life science tools (LST) players. However, it’s already apparent that leadership teams must plan for a wider range of potential scenarios, based on a detailed understanding of how profit pools will evolve. Armed with those insights, companies can make informed decisions to identify the most attractive market segments, innovate to develop new solutions, target M&A opportunities, and differentiate their portfolio of products and services.
The first human genome took nearly 15 years to sequence; today, that process takes less than 24 hours. Costs have declined just as quickly, thanks to NGS technologies. (See Exhibit 1.) The industry is approaching a milestone: a $100 whole genome sequencing (WGS). At the same time, the applications for genomics are expanding. Comprehensive NGS methods such as whole exome sequencing (WES) and WGS are critical tools in profiling tumors and diagnosing rare diseases.
A $100 WGS will not solve all challenges in the industry. Companies will still face long turnaround times, a continued need for sample batching, and expenses for upstream and downstream processes, including data interpretation and management and complicated laboratory workflows. All of these expenses will be more burdensome for small companies, which lack large cores and economies of scale.
Still, lower sequencing costs are already shifting overall competitive dynamics for NGS clinical testing labs and LST companies, in several ways:
In the evolving landscape of genomics, novel research use only (RUO) content is emerging as a key driver of market growth and value creation. RUO content is not approved for any clinical use and thus has a lower regulatory barrier than content designed for patients. However, it can serve as a starting point for companies to validate and innovate for translational and clinical applications. For that reason, recent developments in sequencing require labs to invest in initial RUO content in order to create value downstream.
Adopting incremental and stepwise strategies to introduce new layers of RUO innovation is key to unlocking technologies that provide comprehensive insights and expanded clinical opportunities. A notable example is epigenomics, which plays a significant role in identifying disease mechanisms in complex and rare conditions. This insight is now being applied in the diagnostic field, with commercial tests evaluating abnormal methylation patterns that indicate diseases such as colorectal cancer.
As RUO innovation advances, we can expect to see technologies emerge that are even more transformative, further revolutionizing clinical practice. For example, as noted, the future of NGS content will focus on increasingly multi-omic methodologies with techniques that offer higher resolution, such as spatial analyses. (See Exhibit 2.) However, extended lead times for regulatory approval and reimbursement are likely to temper the immediate impact. For that reason, multi-omics approaches are generating significant interest initially as RUO technologies.
Considering the near-term progress of sequencing innovation—including reduced cost, the shifting dynamics of clinical reimbursement, and evolving regulation—two scenarios emerge:
To better understand these potential market evolutions, we developed a profit pool market analysis based on more than 30 data sources and more than 900 input factors. (See Exhibit 3.) This analysis forecasts US spending in NGS clinical testing and LST from 2023 to 2032, indicating that the future of sequencing profit pools will probably fall between these scenarios.
Today’s NGS clinical testing labs are grappling with profitability challenges, losing around $0.50 per dollar in revenue. Clinical testing labs are struggling with high competition, sub-scale economics, and high costs. In particular, they must invest significantly in R&D and clinical trials. In the future, innovation may come through predicate devices—previously approved or cleared sequencing-based clinical diagnostic tests. Predicate devices can serve as benchmarks for establishing the safety and efficacy of novel diagnostic tools and will spur further innovation by allowing new products to be compared to established technologies. However, these devices are currently limited.
In the cost-pressure scenario, NGS clinical testing labs remains unprofitable. To succeed, companies will need to capitalize on market consolidation among weaker players, along with stable pricing and efficient operations. They will also need strong regulatory expertise to inform investment decisions so they can avoid wasting resources on developing diagnostic products that are not likely to receive approval. Many NGS clinical testing labs will become risk averse, and some could choose to develop tests using sequencers with the largest market share, meaning less competition and slowing price decreases.
However, in the content differentiation scenario, NGS clinical testing labs could reach profit margins of 20% or more, driven by clinical somatic sector volumes. Multi-omics is anticipated to see the highest growth in minimal residual disease and early cancer detection, though growth will vary across tests. Notably, NGS clinical testing lab R&D costs are forecast to decline from 40% to less than 15% of revenue, with selling, general, and administrative costs dropping from 72% to less than 35% of revenue, assuming an increase in scale and business unit synergies.
In contrast to NGS clinical testing labs, LST players are highly profitable and benefit from being paid first as suppliers to labs. LST clinical revenue includes payments for nucleic acid prep, library prep, core consumables, automation amortization, sequencing amortization, and informatics. LST players gain around $0.05 for every dollar in clinical testing lab revenue.
In our analysis, the LST market is expected to remain consistently profitable in both scenarios, benefiting from overall market growth. Tools providers are suppliers in the value chain, with less overall risk exposure to factors such as reimbursement. However, the LST market’s upside is limited compared with the potential for NGS clinical testing labs. Clinical volume is the primary lever impacting LST revenue.
LST companies still need to be thoughtful in how they can best enable NGS clinical testing labs across the two scenarios. In the content differentiation scenario—for example, technological advances, primarily in multi-omics and somatic testing—LST’s revenue distribution is expected to shift toward library preparation, automation, and bioinformatics in the next few years, with above-market compound annual growth rates of greater than 20%. A focus on content differentiation is likely to lead to bioinformatics becoming a more significant revenue driver.
In the cost pressure scenario, LST companies will need to understand their role in supporting NGS clinical testing labs with the regulatory requirements for new sequencing-based tests, potentially through increased investment in regulated instruments and assays to help offset the profitability concerns of NGS clinical testing labs.
For NGS clinical testing lab and LST players, advances in genetic sequencing are changing competitive dynamics and creating a wider range of potential scenarios. Overall, the market will continue to be shaped by efficiency gains, the state of reimbursement, and the regulatory landscape. But these factors will have a huge impact on profitability—and the profitability of the industry as a whole. Companies need to be prepared regardless of how the future unfolds. Several factors can help:
The genomics industry is approaching a new frontier in genetic sequencing. Companies need strategic foresight to successfully adopt new sequencing technologies and develop more advanced genetic diagnostics. Scenario planning can ensure they are prepared for this new environment and can compete successfully, regardless of what the future holds.
The authors wish to thank Otto Liska, Kristen Cook, Sandra Andersen, Johannes Thoms, Bob Lavoie, Matt Prisby, Alec Ludin, Joe Bernardo, Max Schmid, and Kerri McWeeney for their contributions.
Alumnus